多发性骨髓瘤的不断变化的景观:从风险分层到T细胞导向的先进疗法
Carmen Besliu1, Alina Daniela Tanase2, Ionela Rotaru3
1Fortrea Inc., 8 Moore Drive, Durham, NC 27709, USA.
Cancers
|February 13, 2025
概括
多发性髓瘤是一种复杂的血液癌症. 风险分层和像CAR T细胞这样的T细胞导向疗法已经推进了治疗,但这种疾病仍然无法治愈,需要进一步的研究.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 多发性骨髓瘤是一种复杂的,异质的血细胞恶性瘤,通常在老年人中被诊断出来.
- 风险分层工具已经从杜里和鱼系统演变为国际分级系统 (ISS),修订为R-ISS和R2-ISS.
- 治疗方面的进步包括免疫调节药物,蛋白酶体抑制剂和抗CD38抗体,大大改变了治疗模式.
研究的目的:
- 审查多发性骨髓瘤风险分层的演变.
- 提供当前和新兴治疗策略的概述.
- 突出多发性骨髓瘤治疗中的挑战和未得到满足的需求.
主要方法:
- 对多发性骨髓瘤分期系统和治疗进展的文献综述.
- 分析免疫系统功能障碍在多发性骨髓瘤中的作用.
- 讨论新的针对T细胞的疗法,包括CAR T细胞和双特异性抗体.
主要成果:
- 风险分层逐渐改善了预后预测和治疗指导.
- 新型疗法,特别是针对BCMA或GPRC5D的基于T细胞的方法,在复发/耐药性疾病中表现有前途.
- 尽管有进展,多发性骨髓瘤仍然是无法治愈的,外骨髓性疾病和血细胞白血病代表着重要的未满足需求.
结论:
- 持续完善风险分层对于个性化的多发性骨髓瘤管理至关重要.
- 针对T细胞的免疫疗法是一个重大进步,为难以治疗的患者提供了新的希望.
- 进一步的研究对于克服治疗耐药性和治疗多发性骨髓瘤至关重要.
相关概念视频
01:27Tumor Immunotherapy
464
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
464
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:17The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K